AI Tool for Lung Cancer Screening

Overseen By Michael T Lu, MD, MPH

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Massachusetts General Hospital

Disqualifiers: Lung cancer, Recent chest CT, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

1500 Participants Needed

Trial Summary

What is the purpose of this trial?

The goal of this clinical trial is to evaluate whether an AI tool that alerts providers to patients at high 6-year risk of lung cancer based on their chest x-ray images will improve lung cancer screening CT participation. The main question it aims to answer is: Does the AI tool improve lung cancer screening CT participation at 6 months after the baseline outpatient visit The intervention is an alert to the provider to discuss lung cancer screening CT eligibility, for patients considered at high risk of lung cancer based on CXR-LC AI tool. If there is a comparison group: Researchers will compare intervention and non-intervention arms to determine if lung cancer screen CT participation increases.

Eligibility Criteria

This trial is for people aged 50-77 who currently smoke or used to smoke and might be eligible for lung screening according to Medicare guidelines. They must have a scheduled outpatient appointment with a participating provider and a recent chest x-ray.

Inclusion Criteria

I have an upcoming appointment with a participating doctor.

I've had a chest X-ray within the last 2 years.

I am between 50 and 77 years old and have a history of smoking.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Providers receive alerts to discuss lung cancer screening CT eligibility with high-risk patients based on CXR-LC AI tool

6 months

Follow-up

Participants are monitored for lung cancer screening CT participation

6 months

Treatment Details

Interventions

• CXR-LC

Trial Overview The study tests an AI tool (CXR-LC) that alerts doctors about patients at high risk of lung cancer based on chest x-rays, aiming to see if it increases participation in lung cancer screening CTs six months after the initial visit.

Participant Groups

Group I: Intervention Experimental Treatment 1 Intervention

Group II: Non-Intervention Active Control 1 Intervention

Who Is Running the Clinical Trial?

Massachusetts General Hospital

Lead Sponsor

Trials

3,066

Recruited

13,430,000+

Harvard Risk Management Foundation

Collaborator

Trials

7

Recruited

31,100+